AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) will be releasing its earnings data before the market opens on Monday, October 30th. Analysts expect AcelRx Pharmaceuticals to post earnings of ($0.28) per share for the quarter.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.01). The company had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. On average, analysts expect AcelRx Pharmaceuticals to post $-1.11 EPS for the current fiscal year and $-0.86 EPS for the next fiscal year.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) opened at 2.00 on Monday. The company has a 50-day moving average price of $3.59 and a 200 day moving average price of $2.92. The stock’s market cap is $90.76 million. AcelRx Pharmaceuticals, Inc. has a 1-year low of $1.55 and a 1-year high of $5.75.

Several brokerages have recently weighed in on ACRX. Jefferies Group LLC cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. Piper Jaffray Companies restated a “hold” rating and set a $2.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, October 13th. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 1st. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Finally, ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $7.67.

In related news, insider Pamela P. Palmer purchased 10,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $29,500.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Lawrence G. Hamel sold 10,161 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total transaction of $53,751.69. Following the completion of the sale, the insider now owns 16,379 shares in the company, valued at approximately $86,644.91. The disclosure for this sale can be found here. In the last quarter, insiders acquired 37,000 shares of company stock worth $112,280. Corporate insiders own 28.10% of the company’s stock.

WARNING: “AcelRx Pharmaceuticals, Inc. (ACRX) Set to Announce Earnings on Monday” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/23/acelrx-pharmaceuticals-inc-acrx-set-to-announce-earnings-on-monday.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.